Special Section: GFR Decline as an End Point for Clinical Trials in CKDEditorialGFR Decline as an End Point for Clinical Trials in CKD: A View From Europe
Editorial
Section snippets
Acknowledgements
The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the Dutch Medicines Evaluation Board, Lithuanian State Medicines Control Agency, European Medicines Agency, or one of its committees or working parties.
Support: None.
Financial Disclosure: The authors declare that they have no relevant financial interests.
References (19)
- et al.
GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials
Am J Kidney Dis
(2014) - et al.
GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials
Am J Kidney Dis
(2014) - et al.
Utility and validity of estimated GFR–based surrogate time-to-event end points in CKD: a simulation study
Am J Kidney Dis
(2014) - et al.
GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration
Am J Kidney Dis
(2014) - et al.
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
Kidney Int
(2011) Are surrogate markers adequate to assess cardiovascular disease drugs?
JAMA
(1999)- et al.
Rosiglitazone: A European regulatory perspective
Diabetologia
(2011) - European Medicines Agency confirms recommendation to suspend Tredaptive, Pelzont and Trevaclyn [niacin/laropiprant]...
- European Medicines Agency recommends suspension of marketing authorisation for sibutramine [press release]. European...
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.